“JWH-015, a cannabinoid receptor 2 (CB2) agonist has tumor regressive property in various cancer types.
These data confer the impact of this cannabinoid on anti-proliferative and anti-tumorigenic effects, thus enhancing our understanding of its therapeutic efficacy in NSCLC.
Our findings open new avenues for cannabinoid receptor CB2 agonist-JWH-015 as a novel and potential therapeutic target based on EGFR downregulation mechanisms in NSCLC.”
“Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required.
This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales.
The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included.
Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity”
http://www.ncbi.nlm.nih.gov/pubmed/26750641
http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/
“Although marijuana is principally used as a psychoactive substance, it has also been used for medical and religious purposes for over 2000 years.
This review concluded that there was evidence of a positive and moderate short-term trend toward a reduction of pain.
There are a number of reasons why naturally occurring cannabis or cannabinoid drugs might have a pharmacologic effect on headache..
It has been suggested that one explanation for migraine and other headache disorders may be an underlying endocannabinoid deficiency.
…cluster headache attacks were relieved within 5 minutes by the inhalation of marijuana.
Subsequent treatment with dronabinol (THC) 5 mg orally also provided the patient relief within 15 minutes.”
http://www.medscape.com/viewarticle/738529_2
http://www.thctotalhealthcare.com/category/headachemigraine/
“One hundred percent of migraine sufferers in a self-report survey said cannabis reduced migraine pain and discomfort.”
“Cannabis treats a wide variety of conditions, but specific formulations are better for some symptoms than others, patients report in a new landmark survey by a medical cannabis industry company Care By Design.
A full 100 percent of respondents with headaches, migraines, fibromyalgia, irritable bowel syndrome (IBS), and spinal cord injury reported a decrease in pain or discomfort on medical marijuana rich in the molecule cannabidiol (CBD).”
http://blog.sfgate.com/smellthetruth/2015/09/15/survey-medical-pot-treats-migraines/
http://www.thctotalhealthcare.com/category/headachemigraine/
“Our brain’s own endogenous marijuana-like chemicals produce analgesia by modulating the entry of pain signals into the brain at the level of our spinal cord.
Future generations of pain relievers will likely be developed based upon the action of marijuana in the body.
The advantage of targeting the endogenous marijuana system is that only noxious or painful signals are blocked; normal touch sensation is normal.
This study may lead to the development of more effective migraine prevention and treatment.
The challenge will be to find a dose of marijuana that produces pain relief without disturbing normal cognitive function.”
https://www.psychologytoday.com/blog/your-brain-food/201309/marijuana-migraines
http://www.thctotalhealthcare.com/category/headachemigraine/
“No clinical trials are currently available that demonstrate the effects of marijuana on patients with migraine headache; however, the potential effects of cannabinoids on serotonin in the central nervous system indicate that marijuana may be a therapeutic alternative.
Thus, the objective of this study was to describe the effects of medical marijuana on the monthly frequency of migraine headache.
The frequency of migraine headache was decreased with medical marijuana use.
Prospective studies should be conducted to explore a cause-and-effect relationship and the use of different strains, formulations, and doses of marijuana to better understand the effects of medical marijuana on migraine headache treatment and prophylaxis.”
http://www.ncbi.nlm.nih.gov/pubmed/26749285
http://www.thctotalhealthcare.com/category/headachemigraine/
“We investigated associations between adolescent cannabis use and IQ and educational attainment in a sample of 2235 teenagers from the Avon Longitudinal Study of Parents and Children.
After full adjustment, those who had used cannabis ⩾50 times did not differ from never-users on either IQ or educational performance.
Adjusting for group differences in cigarette smoking dramatically attenuated the associations between cannabis use and both outcomes, and further analyses demonstrated robust associations between cigarette use and educational outcomes, even with cannabis users excluded.
These findings suggest that adolescent cannabis use is not associated with IQ or educational performance once adjustment is made for potential confounds, in particular adolescent cigarette use.
Modest cannabis use in teenagers may have less cognitive impact than epidemiological surveys of older cohorts have previously suggested.”
“Multiple Sclerosis (MS) is a global concern disease leading to a progressive, chronic and demyelinating condition, affecting the central nervous system (CNS).
The pathology has an inflammatory/autoimmune origin; nevertheless, neuronal cell death mechanisms are not to be underestimated.
The present study was designed to test the effects of intraperitoneal administration of cannabidiol (CBD), the main non-psychotropiccannabinoid of Cannabis sativa (CS), in an experimental model of MS. The aim is to evaluate the capability of CBD administration to thwart the cascade of mediators involved in MS-induced apoptosis.
We have demonstrated that, alone, purified CBD possesses an anti-apoptotic power against the neurodegenerative processes underlying MS development. This represents an interesting new profile of CBD that could lead to its introduction in the clinical management of MS.”
http://www.ncbi.nlm.nih.gov/pubmed/26744883
http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/
“Abnormal and sometimes severe behavioral and molecular symptoms are usually observed in epileptic humans and animals.
To address this issue, we examined the behavioral and molecular aspects of seizure evoked by pilocarpine. Autophagy can promote both cell survival and death, but there are controversial reports about the neuroprotective or neurodegenerative effects of autophagy in seizure.
Cannabidiol has anticonvulsant properties in some animal models when used as a pretreatment.
In this study, we investigated alteration of seizure scores, autophagy pathway proteins, and antioxidant status in hippocampal cells during the chronic phase of pilocarpine-induced epilepsy after treatment with cannabidiol.
Cannabidiol (100 ng, intracerebroventricular injection) delayed the chronic phase of epilepsy.
Single administration of cannabidiol during the chronic phase of seizure significantly diminished seizure scores such as mouth clonus, head nodding, monolateral and bilateral forelimb clonus and increased the activity of catalase enzyme and reduced glutathione content.
Such a protective effect in the behavioral scores of epileptic rats was also observed after repeated administrations of cannabidiol at the onset of the silent phase.
Moreover, the amount of Atg7, conjugation of Atg5/12, Atg12, and LC3II/LC3I ratio increased significantly in epileptic rats treated with repeated injections of cannabidiol.
In short, our results suggest that post-treatment of Cannabidiol could enhance the induction of autophagy pathway and antioxidant defense in the chronic phase of epilepsy, which could be considered as the protective mechanisms of cannabidiol in a temporal lobe epilepsy model.”
“To assess the effects of cannabis on the ability required to ride a bicycle, repetitive practical cycling tests and medical examinations were carried out before and after inhalative consumption of cannabis.
A maximum of three joints with body weight-adapted THC content (300 μg THC per kg body weight) could be consumed by each test subject.
Fourteen regular cannabis-consuming test subjects were studied (12 males, 2 females).
In summary, only a few driving faults were observed even under the influence of very high THC concentrations. A defined THC concentration that leads to an inability to ride a bicycle cannot be presented.
The test subjects showed only slight distinctive features that can be documented using a medical test routinely run for persons under suspicion of driving under the influence of alcohol or drugs.” http://www.ncbi.nlm.nih.gov/pubmed/26739323
“Alcohol-related deficits were already identifiable at very low blood alcohol concentrations (BAC)s. A significant increase in gross motoric disturbances compared to the soberness state did not regularly occur until a BAC of at least 0.8 g/kg was reached. At the BAC of 1.4 g/kg and above, no test subjects were able to achieve or surpass their sober driving results.” http://www.ncbi.nlm.nih.gov/pubmed/25428289
“The practical ability to ride a bicycle was significantly reduced in the postalcoholic state… The relative cycling performance in the postalcoholic state was comparable to the rides under the influence of BAC of around 0.30 g/kg… it can be assumed that the direct influence of residual blood alcohol levels plays a minor role for the ability to ride a bicycle in the postalcoholic state. Instead, the side effects of the high amounts of alcohol that were consumed the night before are crucial.” http://www.ncbi.nlm.nih.gov/pubmed/25940454
“A defined THC concentration that leads to an inability to ride a bicycle cannot be presented.” http://www.ncbi.nlm.nih.gov/pubmed/26739323